New drug AZD5492 tested for autoimmune diseases in first human study
NCT ID NCT06916806
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times
Summary
This Phase 1 trial tests the safety and tolerability of a new drug called AZD5492 in 72 adults with lupus, myositis, or rheumatoid arthritis. Participants receive one or two doses under the skin and are monitored for side effects and how the drug moves through the body. The study is still recruiting and will last at least 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AZD5492
- What this could lead to
- If successful, this could lead to a new treatment option for people with lupus, myositis, or rheumatoid arthritis.
- What could go wrong
- This is a very early Phase 1 trial with only 72 participants, focused on safety. It is too soon to know if AZD5492 will work or be safe long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC INFLAMMATORY MYOPATHIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
RECRUITINGAnniston, Alabama, 36207, United States
-
Research Site
WITHDRAWNBirmingham, Alabama, 35233, United States
-
Research Site
NOT_YET_RECRUITINGLa Jolla, California, 92037, United States
-
Research Site
NOT_YET_RECRUITINGSacramento, California, 95817, United States
-
Research Site
RECRUITINGIowa City, Iowa, 52242, United States
-
Research Site
NOT_YET_RECRUITINGOmaha, Nebraska, 68198, United States
-
Research Site
NOT_YET_RECRUITINGChapel Hill, North Carolina, 27599, United States
-
Research Site
NOT_YET_RECRUITINGHamilton, Ontario, L8S 4K1, Canada
-
Research Site
RECRUITINGSherbrooke, Quebec, J1G 2E8, Canada
-
Research Site
RECRUITINGBeijing, 100730, China
-
Research Site
RECRUITINGShanghai, 200001, China
-
Research Site
RECRUITINGWuhan, 430022, China
-
Research Site
NOT_YET_RECRUITINGZhengzhou, 450052, China
-
Research Site
RECRUITINGBordeaux, 33000, France
-
Research Site
RECRUITINGMontpellier, 34295, France
-
Research Site
RECRUITINGNancy, 54035, France
-
Research Site
RECRUITINGParis, 75013, France
-
Research Site
RECRUITINGStrasbourg, 67098, France
-
Research Site
RECRUITINGToulouse, 31059, France
-
Research Site
RECRUITINGCologne, 50937, Germany
-
Research Site
RECRUITINGErlangen, 91054, Germany
-
Research Site
NOT_YET_RECRUITINGMagdeburg, 39120, Germany
-
Research Site
RECRUITINGPok Fu Lam, 999077, Hong Kong
-
Research Site
RECRUITINGBunkyō City, 113-8655, Japan
-
Research Site
RECRUITINGKita-gun, 761-0793, Japan
-
Research Site
RECRUITINGKitakyushu-shi, 807-8555, Japan
-
Research Site
RECRUITINGKyoto, 606-8501, Japan
-
Research Site
RECRUITINGNagasaki, 852-8501, Japan
-
Research Site
RECRUITINGAmsterdam, 1105 AZ, Netherlands
-
Research Site
WITHDRAWNLeiden, 2333, Netherlands
-
Research Site
RECRUITINGMérida, 06800, Spain
-
Research Site
RECRUITINGSeville, 41010, Spain
-
Research Site
RECRUITINGValladolid, 47012, Spain
-
Research Site
RECRUITINGGlasgow, G31 2ER, United Kingdom
-
Research Site
RECRUITINGLondon, SE5 9RS, United Kingdom
-
Research Site
RECRUITINGLondon, WC1E 6JF, United Kingdom
-
Research Site
RECRUITINGSouthampton, SO16 6YD, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new shoulder implant restore Pain-Free movement?
- Can a less invasive hip surgery speed up recovery?
- Which hip implant lasts longer? a Head-to-Head trial aims to find out
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers
- Can group learning make biotherapy safer for arthritis patients?
- Can a new biologic tame lupus flares?